biotrakson
pharmaceutical works polpharma s.a. - ceftriaksonas - milteliai injekciniam ar infuziniam tirpalui - 1 g - ceftriaxone
erythromycin tc
tarchomińskie zakłady farmaceutyczne „polfa” spółka akcyjna - eritromicinas - plėvele dengtos tabletės - 200 mg - erythromycin
sitagliptin teva
teva b.v. - sitagliptinas - plėvele dengtos tabletės - 25 mg; 100 mg - sitagliptin
cefotaxime mip
mip pharma gmbh - cefotaksimas - milteliai injekciniam ar infuziniam tirpalui - 1 g; 2 g - cefotaxime
vancomycin cnp
cnp pharma gmbh - vankomicinas - milteliai infuziniam tirpalui - 500 mg; 1000 mg - vancomycin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin